Literature DB >> 25805750

Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy.

Caroline Schmidt-Lucke1, Thomas Zobel2, Sonja Schrepfer3, Uwe Kuhl2, Dong Wang3, Karin Klingel4, Peter Moritz Becher2, Henry Fechner5, Tanja Pozzuto2, Sophie Van Linthout2, Dirk Lassner6, Frank Spillmann2, Felicitas Escher2, Sebastian Holinski7, Hans-Dieter Volk8, Heinz-Peter Schultheiss2, Carsten Tschope9.   

Abstract

Human parvovirus B19 (B19V) is a common pathogen in microvascular disease and cardiomyopathy, owing to infection of endothelial cells. B19V replication, however, is almost restricted to erythroid progenitor cells (ErPCs). Endothelial regeneration attributable to bone marrow-derived circulating angiogenic cells (CACs) is a prerequisite for organ function. Because of many similarities of ErPCs and CACs, we hypothesized that B19V is a perpetrator of impaired endogenous endothelial regeneration. B19V DNA and messenger RNA from endomyocardial biopsy specimens, bone marrow specimens, and circulating progenitor cells were quantified by polymerase chain reaction analysis. The highest B19V DNA concentrations were found in CD34(+)KDR(+) cells from 17 patients with chronic B19V-associated cardiomyopathy. B19V replication intermediates could be detected in nearly half of the patients. Furthermore, chronic B19V infection was associated with impaired endothelial regenerative capacity. B19V infection of CACs in vitro resulted in expression of transcripts encoding B19V proteins. The capsid protein VP1 was identified as a novel inducer of apoptosis, as were nonstructural proteins. Inhibition studies identified so-called death receptor signaling with activation of caspase-8 and caspase-10 to be responsible for apoptosis induction. B19V causally impaired endothelial regeneration with spreading of B19V in CACs in an animal model in vivo. We thus conclude that B19V infection and damage to CACs result in dysfunctional endogenous vascular repair, supporting the emergence of primary bone marrow disease with secondary end-organ damage.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  apoptosis; endothelial progenitor cells; endothelial regeneration; reendothelialization; viruses

Mesh:

Substances:

Year:  2015        PMID: 25805750     DOI: 10.1093/infdis/jiv178

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Clinically suspected myocarditis with pseudo-infarct presentation: the role of endomyocardial biopsy.

Authors:  Alida L P Caforio; Giacomo Malipiero; Renzo Marcolongo; Sabino Iliceto
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Parvovirus B19 integration into human CD36+ erythroid progenitor cells.

Authors:  Tyler Janovitz; Susan Wong; Neal S Young; Thiago Oliveira; Erik Falck-Pedersen
Journal:  Virology       Date:  2017-08-12       Impact factor: 3.616

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.

Authors:  Heinz-Peter Schultheiss; Cornelia Piper; Olaf Sowade; Finn Waagstein; Joachim-Friedrich Kapp; Karl Wegscheider; Georg Groetzbach; Matthias Pauschinger; Felicitas Escher; Eloisa Arbustini; Harald Siedentop; Uwe Kuehl
Journal:  Clin Res Cardiol       Date:  2016-04-25       Impact factor: 5.460

5.  Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients.

Authors:  Heinz-Peter Schultheiss; Thomas Bock; Heiko Pietsch; Ganna Aleshcheva; Christian Baumeier; Friedrich Fruhwald; Felicitas Escher
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

6.  Phosphorylated STAT5 directly facilitates parvovirus B19 DNA replication in human erythroid progenitors through interaction with the MCM complex.

Authors:  Safder S Ganaie; Wei Zou; Peng Xu; Xuefeng Deng; Steve Kleiboeker; Jianming Qiu
Journal:  PLoS Pathog       Date:  2017-05-01       Impact factor: 6.823

Review 7.  Recent Advances in Replication and Infection of Human Parvovirus B19.

Authors:  Safder S Ganaie; Jianming Qiu
Journal:  Front Cell Infect Microbiol       Date:  2018-06-05       Impact factor: 5.293

8.  Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity.

Authors:  Sophie Van Linthout; Ahmed Elsanhoury; Oliver Klein; Marzena Sosnowski; Kapka Miteva; Dirk Lassner; Mohamed Abou-El-Enein; Burkert Pieske; Uwe Kühl; Carsten Tschöpe
Journal:  ESC Heart Fail       Date:  2018-08-11

9.  Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells.

Authors:  Thomas Zobel; C-Thomas Bock; Uwe Kühl; Maria Rohde; Dirk Lassner; Heinz-Peter Schultheiss; Caroline Schmidt-Lucke
Journal:  Viruses       Date:  2019-03-06       Impact factor: 5.048

10.  Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all-comer population of patients with heart failure: a retrospective analysis.

Authors:  Efthymios Sotiriou; Susanne Heiner; Thomas Jansen; Moritz Brandt; Kai Helge Schmidt; Karl-Friedrich Kreitner; Tilman Emrich; Heinz-Peter Schultheiss; Eberhard Schulz; Thomas Münzel; Philip Wenzel
Journal:  ESC Heart Fail       Date:  2018-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.